Highly Expressed Genes in Pancreatic Ductal Adenocarcinomas

A Comprehensive Characterization and Comparison of the Transcription Profiles Obtained from Three Major Technologies

Christine A. Iacobuzio-Donahue, Raheela Ashfaq, Anirban Maitra, N. Volkan Adsay, Grace L. Shen-Ong, Karin Berg, Michael A Hollingsworth, John L. Cameron, Charles J. Yeo, Scott E. Kern, Michael Goggins, Ralph H. Hruban

Research output: Contribution to journalArticle

348 Citations (Scopus)

Abstract

When using gene expression profiling to understand human tumors, one is often confronted with long lists of genes that need to be further categorized into meaningful data. We performed a comprehensive evaluation and comparison of gene expression profiles obtained from pancreatic cancers to determine those genes most differentially expressed and thus with the most promise for translation into clinically useful targets. cDNA was prepared from 50 samples of normal pancreas or duodenal mucosal tissues, 7 samples of chronic pancreatitis, and 39 samples of pancreas cancer tissues or cancer cell lines and hybridized to the complete Affymetrix Human Genome U133 GeneChip set (arrays U133A and U133B) for simultaneous analysis of 45,000 fragments corresponding to 33,000 known genes and 6,000 expressed sequence tags. Genes expressed at levels at least 3-fold greater in the pancreatic cancers as compared with nonneoplastic tissues were identified. Three hundred seventy-seven Affymetrix fragments were identified as having ≥3-fold expression levels in pancreas cancer specimens as compared with nonneoplastic tissues, corresponding to 234 known genes. Serial analysis of gene expression libraries (http://www.ncbi.nlm.nih.gov/SAGE/) of two normal pancreatic ductal cell cultures (HX and H126) were used to exclude 17 genes with high expression levels in the normal duct epithelium (more than five tags/library). Of the remaining 217 known genes, 75 have been previously reported as highly expressed in pancreatic cancers, while the remaining 142 genes are novel. We used principal components analysis (PCA) to identify the genes among these 217 identified as the most differentially expressed and specific to pancreatic cancer tissues or cell lines. Among the most differentially expressed genes identified by PCA were Mesothelin, Muc4, Muc5A/C, Kallikrein 10, Transglutaminase 2, Fascin, TMPRSS3 and stratifin. The differential expression identified by PCA for these genes indicates they are among the more attractive targets for novel therapeutic targets, tumor markers, or as a means of screening pancreatic cancer samples for information regarding tumor classification or potential therapeutic responses. Our findings were also compared in detail to the previously reported findings of highly expressed genes in other studies of global gene expression in pancreatic cancers. We found that robust changes in gene expression were most often identified by more than one gene expression platform. Forty genes were identified by more than one method (U133 oligonucleotide arrays, cDNA arrays or serial analysis of gene expression), and 6 of these genes were identified by all three methods. Our findings identify a novel set of genes as highly expressed in pancreatic cancer, validate the differential expression of previously reported genes, and provide additional support for those genes most differentially expressed to be translated into clinically useful targets.

Original languageEnglish (US)
Pages (from-to)8614-8622
Number of pages9
JournalCancer Research
Volume63
Issue number24
StatePublished - Dec 15 2003

Fingerprint

Adenocarcinoma
Technology
Pancreatic Neoplasms
Genes
Gene Expression
Principal Component Analysis
Oligonucleotide Array Sequence Analysis
Cell Line
Neoplasms
Kallikreins
Expressed Sequence Tags
Chronic Pancreatitis
Gene Expression Profiling
Human Genome
Tumor Biomarkers
Gene Library
Transcriptome
Libraries
Pancreas
Mucous Membrane

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Iacobuzio-Donahue, C. A., Ashfaq, R., Maitra, A., Adsay, N. V., Shen-Ong, G. L., Berg, K., ... Hruban, R. H. (2003). Highly Expressed Genes in Pancreatic Ductal Adenocarcinomas: A Comprehensive Characterization and Comparison of the Transcription Profiles Obtained from Three Major Technologies. Cancer Research, 63(24), 8614-8622.

Highly Expressed Genes in Pancreatic Ductal Adenocarcinomas : A Comprehensive Characterization and Comparison of the Transcription Profiles Obtained from Three Major Technologies. / Iacobuzio-Donahue, Christine A.; Ashfaq, Raheela; Maitra, Anirban; Adsay, N. Volkan; Shen-Ong, Grace L.; Berg, Karin; Hollingsworth, Michael A; Cameron, John L.; Yeo, Charles J.; Kern, Scott E.; Goggins, Michael; Hruban, Ralph H.

In: Cancer Research, Vol. 63, No. 24, 15.12.2003, p. 8614-8622.

Research output: Contribution to journalArticle

Iacobuzio-Donahue, CA, Ashfaq, R, Maitra, A, Adsay, NV, Shen-Ong, GL, Berg, K, Hollingsworth, MA, Cameron, JL, Yeo, CJ, Kern, SE, Goggins, M & Hruban, RH 2003, 'Highly Expressed Genes in Pancreatic Ductal Adenocarcinomas: A Comprehensive Characterization and Comparison of the Transcription Profiles Obtained from Three Major Technologies', Cancer Research, vol. 63, no. 24, pp. 8614-8622.
Iacobuzio-Donahue, Christine A. ; Ashfaq, Raheela ; Maitra, Anirban ; Adsay, N. Volkan ; Shen-Ong, Grace L. ; Berg, Karin ; Hollingsworth, Michael A ; Cameron, John L. ; Yeo, Charles J. ; Kern, Scott E. ; Goggins, Michael ; Hruban, Ralph H. / Highly Expressed Genes in Pancreatic Ductal Adenocarcinomas : A Comprehensive Characterization and Comparison of the Transcription Profiles Obtained from Three Major Technologies. In: Cancer Research. 2003 ; Vol. 63, No. 24. pp. 8614-8622.
@article{8babce052d7b42b391f7e70b9c58ab07,
title = "Highly Expressed Genes in Pancreatic Ductal Adenocarcinomas: A Comprehensive Characterization and Comparison of the Transcription Profiles Obtained from Three Major Technologies",
abstract = "When using gene expression profiling to understand human tumors, one is often confronted with long lists of genes that need to be further categorized into meaningful data. We performed a comprehensive evaluation and comparison of gene expression profiles obtained from pancreatic cancers to determine those genes most differentially expressed and thus with the most promise for translation into clinically useful targets. cDNA was prepared from 50 samples of normal pancreas or duodenal mucosal tissues, 7 samples of chronic pancreatitis, and 39 samples of pancreas cancer tissues or cancer cell lines and hybridized to the complete Affymetrix Human Genome U133 GeneChip set (arrays U133A and U133B) for simultaneous analysis of 45,000 fragments corresponding to 33,000 known genes and 6,000 expressed sequence tags. Genes expressed at levels at least 3-fold greater in the pancreatic cancers as compared with nonneoplastic tissues were identified. Three hundred seventy-seven Affymetrix fragments were identified as having ≥3-fold expression levels in pancreas cancer specimens as compared with nonneoplastic tissues, corresponding to 234 known genes. Serial analysis of gene expression libraries (http://www.ncbi.nlm.nih.gov/SAGE/) of two normal pancreatic ductal cell cultures (HX and H126) were used to exclude 17 genes with high expression levels in the normal duct epithelium (more than five tags/library). Of the remaining 217 known genes, 75 have been previously reported as highly expressed in pancreatic cancers, while the remaining 142 genes are novel. We used principal components analysis (PCA) to identify the genes among these 217 identified as the most differentially expressed and specific to pancreatic cancer tissues or cell lines. Among the most differentially expressed genes identified by PCA were Mesothelin, Muc4, Muc5A/C, Kallikrein 10, Transglutaminase 2, Fascin, TMPRSS3 and stratifin. The differential expression identified by PCA for these genes indicates they are among the more attractive targets for novel therapeutic targets, tumor markers, or as a means of screening pancreatic cancer samples for information regarding tumor classification or potential therapeutic responses. Our findings were also compared in detail to the previously reported findings of highly expressed genes in other studies of global gene expression in pancreatic cancers. We found that robust changes in gene expression were most often identified by more than one gene expression platform. Forty genes were identified by more than one method (U133 oligonucleotide arrays, cDNA arrays or serial analysis of gene expression), and 6 of these genes were identified by all three methods. Our findings identify a novel set of genes as highly expressed in pancreatic cancer, validate the differential expression of previously reported genes, and provide additional support for those genes most differentially expressed to be translated into clinically useful targets.",
author = "Iacobuzio-Donahue, {Christine A.} and Raheela Ashfaq and Anirban Maitra and Adsay, {N. Volkan} and Shen-Ong, {Grace L.} and Karin Berg and Hollingsworth, {Michael A} and Cameron, {John L.} and Yeo, {Charles J.} and Kern, {Scott E.} and Michael Goggins and Hruban, {Ralph H.}",
year = "2003",
month = "12",
day = "15",
language = "English (US)",
volume = "63",
pages = "8614--8622",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Highly Expressed Genes in Pancreatic Ductal Adenocarcinomas

T2 - A Comprehensive Characterization and Comparison of the Transcription Profiles Obtained from Three Major Technologies

AU - Iacobuzio-Donahue, Christine A.

AU - Ashfaq, Raheela

AU - Maitra, Anirban

AU - Adsay, N. Volkan

AU - Shen-Ong, Grace L.

AU - Berg, Karin

AU - Hollingsworth, Michael A

AU - Cameron, John L.

AU - Yeo, Charles J.

AU - Kern, Scott E.

AU - Goggins, Michael

AU - Hruban, Ralph H.

PY - 2003/12/15

Y1 - 2003/12/15

N2 - When using gene expression profiling to understand human tumors, one is often confronted with long lists of genes that need to be further categorized into meaningful data. We performed a comprehensive evaluation and comparison of gene expression profiles obtained from pancreatic cancers to determine those genes most differentially expressed and thus with the most promise for translation into clinically useful targets. cDNA was prepared from 50 samples of normal pancreas or duodenal mucosal tissues, 7 samples of chronic pancreatitis, and 39 samples of pancreas cancer tissues or cancer cell lines and hybridized to the complete Affymetrix Human Genome U133 GeneChip set (arrays U133A and U133B) for simultaneous analysis of 45,000 fragments corresponding to 33,000 known genes and 6,000 expressed sequence tags. Genes expressed at levels at least 3-fold greater in the pancreatic cancers as compared with nonneoplastic tissues were identified. Three hundred seventy-seven Affymetrix fragments were identified as having ≥3-fold expression levels in pancreas cancer specimens as compared with nonneoplastic tissues, corresponding to 234 known genes. Serial analysis of gene expression libraries (http://www.ncbi.nlm.nih.gov/SAGE/) of two normal pancreatic ductal cell cultures (HX and H126) were used to exclude 17 genes with high expression levels in the normal duct epithelium (more than five tags/library). Of the remaining 217 known genes, 75 have been previously reported as highly expressed in pancreatic cancers, while the remaining 142 genes are novel. We used principal components analysis (PCA) to identify the genes among these 217 identified as the most differentially expressed and specific to pancreatic cancer tissues or cell lines. Among the most differentially expressed genes identified by PCA were Mesothelin, Muc4, Muc5A/C, Kallikrein 10, Transglutaminase 2, Fascin, TMPRSS3 and stratifin. The differential expression identified by PCA for these genes indicates they are among the more attractive targets for novel therapeutic targets, tumor markers, or as a means of screening pancreatic cancer samples for information regarding tumor classification or potential therapeutic responses. Our findings were also compared in detail to the previously reported findings of highly expressed genes in other studies of global gene expression in pancreatic cancers. We found that robust changes in gene expression were most often identified by more than one gene expression platform. Forty genes were identified by more than one method (U133 oligonucleotide arrays, cDNA arrays or serial analysis of gene expression), and 6 of these genes were identified by all three methods. Our findings identify a novel set of genes as highly expressed in pancreatic cancer, validate the differential expression of previously reported genes, and provide additional support for those genes most differentially expressed to be translated into clinically useful targets.

AB - When using gene expression profiling to understand human tumors, one is often confronted with long lists of genes that need to be further categorized into meaningful data. We performed a comprehensive evaluation and comparison of gene expression profiles obtained from pancreatic cancers to determine those genes most differentially expressed and thus with the most promise for translation into clinically useful targets. cDNA was prepared from 50 samples of normal pancreas or duodenal mucosal tissues, 7 samples of chronic pancreatitis, and 39 samples of pancreas cancer tissues or cancer cell lines and hybridized to the complete Affymetrix Human Genome U133 GeneChip set (arrays U133A and U133B) for simultaneous analysis of 45,000 fragments corresponding to 33,000 known genes and 6,000 expressed sequence tags. Genes expressed at levels at least 3-fold greater in the pancreatic cancers as compared with nonneoplastic tissues were identified. Three hundred seventy-seven Affymetrix fragments were identified as having ≥3-fold expression levels in pancreas cancer specimens as compared with nonneoplastic tissues, corresponding to 234 known genes. Serial analysis of gene expression libraries (http://www.ncbi.nlm.nih.gov/SAGE/) of two normal pancreatic ductal cell cultures (HX and H126) were used to exclude 17 genes with high expression levels in the normal duct epithelium (more than five tags/library). Of the remaining 217 known genes, 75 have been previously reported as highly expressed in pancreatic cancers, while the remaining 142 genes are novel. We used principal components analysis (PCA) to identify the genes among these 217 identified as the most differentially expressed and specific to pancreatic cancer tissues or cell lines. Among the most differentially expressed genes identified by PCA were Mesothelin, Muc4, Muc5A/C, Kallikrein 10, Transglutaminase 2, Fascin, TMPRSS3 and stratifin. The differential expression identified by PCA for these genes indicates they are among the more attractive targets for novel therapeutic targets, tumor markers, or as a means of screening pancreatic cancer samples for information regarding tumor classification or potential therapeutic responses. Our findings were also compared in detail to the previously reported findings of highly expressed genes in other studies of global gene expression in pancreatic cancers. We found that robust changes in gene expression were most often identified by more than one gene expression platform. Forty genes were identified by more than one method (U133 oligonucleotide arrays, cDNA arrays or serial analysis of gene expression), and 6 of these genes were identified by all three methods. Our findings identify a novel set of genes as highly expressed in pancreatic cancer, validate the differential expression of previously reported genes, and provide additional support for those genes most differentially expressed to be translated into clinically useful targets.

UR - http://www.scopus.com/inward/record.url?scp=9144241047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9144241047&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 8614

EP - 8622

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 24

ER -